Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174062
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pino Saladrigues, Marta del | - |
dc.contributor.author | Martí, Cristina | - |
dc.contributor.author | Torras, Ines | - |
dc.contributor.author | Henere, Carla | - |
dc.contributor.author | Munmany, Meritxell | - |
dc.contributor.author | Marimon, Lorena | - |
dc.contributor.author | Saco, Adela | - |
dc.contributor.author | Torné Bladé, Aureli | - |
dc.contributor.author | Ordi i Majà, Jaume | - |
dc.date.accessioned | 2021-02-22T07:31:42Z | - |
dc.date.available | 2021-02-22T07:31:42Z | - |
dc.date.issued | 2020-05-23 | - |
dc.identifier.issn | 2076-393X | - |
dc.identifier.uri | http://hdl.handle.net/2445/174062 | - |
dc.description.abstract | Background: Recent studies have shown preliminary evidence that vaccination against human papillomavirus (HPV) could decrease the risk of persistent/recurrent HSIL in women treated for high-grade cervical intraepithelial lesion (HSIL). We aimed to determine the benefits of HPV vaccination in patients undergoing conization for HSIL in real-life conditions and evaluate vaccination compliance associated with different funding policies. Methods: From January 2013 to July 2018, 265 women underwent conization in our center. From January 2013 to July 2017, treated patients (n = 131) had to pay for the vaccine, whereas after July 2017 the vaccine was publicly funded and free for treated women (n = 134). Post-conization follow-up controls were scheduled every six months with a Pap smear, HPV testing, and a colposcopy. Results: 153 (57.7%) women accepted vaccination (vaccinated group), and 112 (42.3%) refused the vaccine (non-vaccinated group). Persistent/recurrent HSIL was less frequent in vaccinated than in non-vaccinated women (3.3% vs. 10.7%, p = 0.015). HPV vaccination was associated with a reduced risk of persistent/recurrent HSIL (OR 0.2, 95%CI: 0.1–0.7, p = 0.010). Vaccination compliance increased when the vaccine was publicly funded (from 35.9% [47/131] to 79.1% [106/134], p < 0.001). Conclusions: HPV vaccination in women undergoing conization is associated with a 4.5-fold reduction in the risk of persistent/recurrent HSIL. Vaccination policies have an important impact on vaccination compliance. | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: http://dx.doi.org/10.3390/vaccines8020245 | - |
dc.relation.ispartof | Vaccines, 2020, vol. 8, num. 2 | - |
dc.relation.uri | http://dx.doi.org/10.3390/vaccines8020245 | - |
dc.rights | cc by (c) Pino Saladrigues et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | - |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Vacuna del papil·lomavirus | - |
dc.subject.classification | Tumors | - |
dc.subject.other | Papillomavirus vaccines | - |
dc.subject.other | Tumors | - |
dc.title | HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-02-19T19:00:46Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 32456136 | - |
Appears in Collections: | Articles publicats en revistes (ISGlobal) Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Del_Pino_M_Vaccines_Basel_2020.pdf | 596.22 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License